secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001437749-23-016922
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris discontinues respiratory collaboration with Genentech for scientific reasons
--------------------------------------------------------------------------------

- Pieris and Genentech jointly ended the respiratory program in May 2023.
- Program aimed at locally delivered respiratory therapies using Pieris' Anticalin technology.
- Discontinuation attributed to scientific reasons; no financial terms disclosed.
- Pieris furnished a June 2023 investor presentation (Exhibit 99.1) with no updated guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923016922/0001437749-23-016922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774923016922/pirs20230601_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-016922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer